## Note
nid: 1518967155386
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Ipilimumab, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Pembrolizumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Ipilimumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Pembrolizumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::Cancer_Immunotherapy, #AK_Step1_v11::#UWorld::10000-99999::16000-16999::16895, #AK_Step1_v11::$AnKingUpdates::$Errata::bonus, #AK_Step1_v11::^Other::^EXPN::BGadd, #AK_Step1_v11::^Other::^FA_Updates::FA2018, #AK_Step1_v11::^Other::^HighYield::3-HighYield-temporary
markdown: false

### Text
<b>Ipilimumab</b> and <b>Pembrolizumab</b> are monoclonal
antibodies that work by downregulating {{c1::immune tolerance}}
mechanisms
<div>
  <i>*bonus: their respective targets:</i>
</div>

### Extra
- Ipilimumab is an immunotherapy that targets <b>CTLA-4</b>
(normally functions in turning off cytotoxic T cells, helps
anti-cancer T cells to avoid cancer immune escape)
<div>
  - Pembrolizumab (and Nivolumab) binds PD-1, preventing PD-L1 on
  cancer cells from inactivating anti-cancer T cells
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

